Excellarate

Excellarate (also known as GAM501) is a DNA-activated collagen gel developed for the topical treatment of chronic wounds, specifically diabetic foot ulcers. It utilizes a replication-deficient adenoviral vector (Ad5) to deliver the human platelet-derived growth factor-B (PDGF-B) gene directly to the wound site. The vector is formulated within a bovine collagen matrix, which serves as both a delivery vehicle and a scaffold for tissue repair. Once applied, the adenovector transfects local cells, inducing the transient expression and secretion of PDGF-B protein. This growth factor stimulates angiogenesis, fibroblast proliferation, and granulation tissue formation, thereby accelerating the healing of non-healing ulcers. Originally developed by Tissue Repair Company and later acquired by Cardium Therapeutics, the product completed Phase 2b clinical trials but development was subsequently discontinued.

Brand names

Excellarate

Other names

DNA-activated collagen gelAd5-PDGF-B collagen gelAd-5-PDGF-B collagen gelAd 5-PDGF-B collagen gel